Aquestive Therapeutics, Inc. (NASDAQ:AQST) Sees Large Growth in Short Interest

Aquestive Therapeutics, Inc. (NASDAQ:AQST) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totalling 10,480,000 shares, a growth of 8.6% from the December 15th total of 9,650,000 shares. Based on an average daily volume of 1,550,000 shares, the short-interest ratio is currently 6.8 days.

Hedge Funds Weigh In On Aquestive Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AQST. Victory Capital Management Inc. bought a new stake in Aquestive Therapeutics during the 2nd quarter worth approximately $27,000. nVerses Capital LLC acquired a new position in Aquestive Therapeutics in the third quarter worth $28,000. The Manufacturers Life Insurance Company bought a new stake in shares of Aquestive Therapeutics during the second quarter worth $76,000. Harvey Capital Management Inc. acquired a new stake in shares of Aquestive Therapeutics in the third quarter valued at $88,000. Finally, Intech Investment Management LLC acquired a new stake in shares of Aquestive Therapeutics in the third quarter valued at approximately $90,000. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on AQST. Cantor Fitzgerald initiated coverage on Aquestive Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $17.00 target price on the stock. JMP Securities reissued a “market outperform” rating and set a $9.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a report on Friday, December 20th. Finally, Leerink Partners upped their price target on Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $11.00.

Aquestive Therapeutics Trading Up 0.3 %

Shares of NASDAQ:AQST opened at $3.10 on Tuesday. Aquestive Therapeutics has a 1-year low of $2.24 and a 1-year high of $6.23. The firm has a market capitalization of $282.66 million, a PE ratio of -6.89 and a beta of 2.71. The business’s 50 day moving average is $3.93 and its 200-day moving average is $4.19.

Aquestive Therapeutics (NASDAQ:AQST) last posted its earnings results on Monday, November 4th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The company had revenue of $13.54 million during the quarter, compared to analyst estimates of $12.69 million. During the same period in the previous year, the business earned ($0.03) EPS. On average, sell-side analysts predict that Aquestive Therapeutics will post -0.46 EPS for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.